Purpose There is as yet no optimal treatment regimen for patients with epidermal growth
factor receptor (EGFR) gene wild-type non-small-cell lung cancer (NSCLC) that has …

Objective There are few standard therapeutic options beyond second-line treatment. We
aimed to evaluate the efficacy and safety of erlotinib monotherapy as third-line …

To evaluate the efficacy and safety of erlotinib for non-small cell lung cancer (NSCLC), we
performed a population-based observational study. The study involved 307 patients treated …

Background Epidermal growth factor receptor (EGFR) mutations are associated with
sensitivity to gefitinib or erlotinib in non-small cell lung cancer (NSCLC). We investigated the …

Purpose: Most lung cancers with activating epidermal growth factor receptor (EGFR)
mutations respond to gefitinib; however, resistance to this tyrosine kinase inhibitor (TKI) …

Abstract Introduction In 2006, the Vila Nova de Gaia/Espinho Hospital Centre Pulmonary
Oncology Unit started performing EGFR (Epidermal Growth Factor Receptor) mutation …

Introduction• Literature review‐Molecular biology of EGFR mutations‐Clinical characteristics
of NSCLC patients with EGFR mutations‐Genetic characteristics of EGFR‐mutated tumours …

Purpose: Somatic mutations in the epidermal growth factor receptor (EGFR) have been
detected in patients with non–small cell lung cancer (NSCLC) and are associated with …

Overexpression and mutational activation of the epidermal growth factor receptor (EGFR) is
involved in tumor development and progression in non-small-cell lung cancer (NSCLC) …

Background The tyrosine kinase inhibitor erlotinib improves the outcomes of patients with
advanced non-small-cell lung carcinoma (NSCLC) harbouring epidermal growth factor …